In vitro  efficacy of tyrosine kinase inhibitors: SYK and BCR‐ABL inhibitors in lymphomas | Zendy

Rinaldi Andrea | Zendy; Ponzoni Maurilio | Zendy; Uccella Silvia | Zendy; Rossi Davide | Zendy; Gaidano Gianluca | Zendy; Facchetti Fabio | Zendy; Pruneri Giancarlo | Zendy; Tibiletti Maria Grazia | Zendy; Capella Carlo | Zendy; Zucca Emanuele | Zendy; Doglioni Claudio | Zendy; Catapano Carlo | Zendy; Bertoni Francesco | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

In vitro efficacy of tyrosine kinase inhibitors: SYK and BCR‐ABL inhibitors in lymphomas

Author(s) -

Rinaldi Andrea,

Ponzoni Maurilio,

Uccella Silvia,

Rossi Davide,

Gaidano Gianluca,

Facchetti Fabio,

Pruneri Giancarlo,

Tibiletti Maria Grazia,

Capella Carlo,

Zucca Emanuele,

Doglioni Claudio,

Catapano Carlo,

Bertoni Francesco

Publication year - 2011

Publication title -

hematological oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.918

H-Index - 44

eISSN - 1099-1069

pISSN - 0278-0232

DOI - 10.1002/hon.981

Subject(s) - syk , cancer research , tyrosine kinase , in vitro , medicine , kinase , chemistry , receptor , biochemistry

The B cell receptor (BCR) signalling pathway is believed to play a major role in B cell lymphoma growth and survival [1,2]. SYK is a critical non-receptor tyrosine kinase involved in the BCR signalling, that, when activated, leads to intracellular calcium mobilization, activation of AKT, mitogen-activated protein kinases and NFkB. A relatively strong expression of SYK can be demonstrated in the vast majority of non-Hodgkin lymphoma subtypes [3], and inhibition of SYK has been

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research